Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress.
| THOUSAND OAKS, Calif., Sept. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress. On Monday, Oct. 4, 2021, at 8:30 a.m. ET, David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen’s management team, will discuss clinical data being presented at EADV, including data from the AMG 451/KHK4083 Phase 2 trial in patients with moderate-to-severe atopic dermatitis, as well as our broader inflammation portfolio. Live audio of the investor call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen’s business given at certain investor and medical conferences, can be accessed on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. CONTACT: Amgen, Thousand Oaks
SOURCE Amgen | ||
Company Codes: NASDAQ-NMS:AMGN |
View original content to download multimedia:
